Chief Medical Officer Of Provention Bio Inc. (PRVB) Has Bought 5,201 Of The Company’s Shares

BEPC Stock
BEPC Stock

The stock of Provention Bio Inc. (NASDAQ:PRVB) increased by $1.12 on Tuesday to finish at $8.89, up 14.41 percent. The last five days have seen an average of 4,863,920 shares of common stock traded. 10 times new highs were reached in the current year, with a gain of $3.27. The average number of shares traded over the last 20 days was 2,970,940, while the average volume over the last 50 days totaled 2,027,244.

PRVB stock appreciated 33.28% since last month. On 10/28/22, the company’s shares reached a one-month low of $6.38. The stock touched a high of $9.65 on 11/14/22, after rallying from a low of $3.18 in 52 weeks. The price of PRVB stock has risen by 58.19% or $3.27 this year, reaching a new high 10 times. Still, the stock price is down -7.92% from the 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Insider Transactions

PRVB stock investors should be aware that Provention Bio Inc. (PRVB) stock had its last reported insider trading activity 355 days ago on Dec 03. On Dec 03, Chief Medical Officer Ramos Eleanor acquired 5,201 shares at $6.49 each. This transaction resulted in the insider spending $33,765. On Nov 30, Palmer Ashleigh added 3,750 shares at a price of US$6.66. After the transaction, the insider now owns 2,570,050 shares. Chief Scientific Officer Leon Francisco had earlier bought 5,550 shares on Nov 24 for $7.24 a share. The transaction was completed for $40,188.

Valuation Metrics

Beta for the stock is 2.37. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 282.32, the price-to-book (PB) ratio of 5.11.

Financial Health

For the three months ended September 29, Provention Bio Inc.’s quick ratio was 7.60, while its current ratio was 7.60, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending September 29 is 0.16, and the total debt to equity ratio is 0.16. Based on annual data, it had gross profit of $116.97 million and revenue of $1.4 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. PRVB’s return on assets (ROA) during the last 12 months has been -76.30%. There was a -103.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -99.10%.

Earnings Surprise

According to Provention Bio Inc.’s quarterly financial report for the quarter that ended September 29, it had $26.64 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.75 million, while revenues rose by 100.0% to $0.58 million. It was predicted that Provention Bio Inc.’s quarterly earnings would be -$0.34, but it ended up being -$0.42, beating the consensus by 19.00%. EBITDA was -$28.84 million for the quarter. At the end of Provention Bio Inc.’s most recent quarter ended September 29, its liabilities totaled 49.14 million, while its total debt was $23.92 million. Equity owned by shareholders amounts to $87.19 million.

Technical Picture

Here’s a quick look at Provention Bio Inc.’s (PRVB) price momentum from a technical perspective. As of 22 November, the RSI 9-day stood at 63.00%, suggesting the stock is Neutral, with a 108.81% historical volatility rate.

The stochastic %K and %D were 53.88% and 52.85% respectively, while the average true range (ATR) was 0.91. Based on the 14-day stochastic reading of 74.95%, the RSI (14) reading is 62.47%. On the 9-day MACD Oscillator, the stock is at -0.20, and the 14-day reading is at 0.12.

Analyst Ratings

In its analyst report released on September 20, 2022, Jefferies began covering Provention Bio Inc. (NASDAQ: PRVB). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Provention Bio Inc. (PRVB) an Buy rating. PRVB is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 7 others recommend it as a buy.

What is PRVB’s price target for the next 12 months?

The current consensus forecast for the stock is between $9.00 and $30.00, with a median target price of $18.00. In analyzing these forecasts, the average price target given by analysts for Provention Bio Inc. (PRVB) is $17.88.


Please enter your comment!
Please enter your name here